Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil.
Observatório de Pesquisa em Epidemiologia, Nutrição e Saúde (OPeNS), Belo Horizonte, Brazil.
Int J Obes (Lond). 2024 Jan;48(1):44-54. doi: 10.1038/s41366-023-01399-x. Epub 2023 Nov 7.
Obesity poses a significant public health challenge. Research has examined the impact of cannabis and subproducts on health but varying results have hindered a consensus.
This study aimed to evaluated the effects of cannabis and subproducts on body measurements.
For searching randomized controlled trials evaluating cannabis and/or subproducts use and changes in anthropometric measures, a systematic search at MEDLINE, Embase, Cochrane Library and Web of Science was conducted until March 2023. The outcomes included changes in body weight, body mass index (BMI) and waist circumference (WC). Meta-analysis was realized using R software (version 4.2.1).
In general, cannabis use reduced weight by 1.87 kg (95% CI: -3.71 to -0.03) and WC (mean difference = -2.19, 95% CI: -4.44 to 0.06). When examining subgroups, longer follow-up periods were associated with a more pronounced BMI reduction (mean difference = -1.10, 95% CI: -2.23 to 0.03). Cannabinoid CB1 exhibited an increase in body fat (mean difference = 1.70, 95% CI: 0.66-2.74).
These findings suggest that cannabis and subproducts could be considered adjuncts in obesity treatment by helping to reduce relevant anthropometric measurements.
肥胖对公共健康构成重大挑战。研究已经研究了大麻和次级产品对健康的影响,但不同的结果阻碍了共识的形成。
本研究旨在评估大麻和次级产品对身体测量的影响。
为了搜索评估大麻和/或次级产品使用与人体测量学变化的随机对照试验,我们在 MEDLINE、Embase、Cochrane 图书馆和 Web of Science 进行了系统搜索,截止日期为 2023 年 3 月。结果包括体重、体重指数(BMI)和腰围(WC)的变化。使用 R 软件(版本 4.2.1)进行荟萃分析。
总体而言,大麻使用使体重降低了 1.87 公斤(95%置信区间:-3.71 至 -0.03)和 WC(平均差异=-2.19,95%置信区间:-4.44 至 0.06)。在检查亚组时,较长的随访期与 BMI 降低更为显著相关(平均差异=-1.10,95%置信区间:-2.23 至 0.03)。大麻素 CB1 显示体脂肪增加(平均差异=1.70,95%置信区间:0.66-2.74)。
这些发现表明,大麻和次级产品可以被视为肥胖治疗的辅助手段,有助于减少相关的人体测量学测量。